SARAH and SIRveNIB
Two large trials found radioactive beads were gentler than sorafenib but did not help patients live longer.
SARAH (n=459): OS 8.0 vs 9.9 months (HR 1.15, not significant); SIRveNIB (n=360): OS 8.8 vs 10.0 months (HR 1.12). Better quality of life and response with Y-90. Interpreted as showing the need for personalised dosimetry and earlier-stage use rather than the failure of the modality.
- Median 8 vs 9.9 months with Y-90 SIRT compared with Sorafenib; about 1.9 months shorter for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 15 percent higher chance of the event at any given time (hazard ratio 1.15).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Locally advanced HCC: yttrium-90 radioembolisation vs sorafenib. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival (SARAH)primary | Y-90 SIRT | 237 | 8 months | 1.15 | — | — |
| Sorafenib | 222 | 9.9 months |
Pages like this
not linked directly; found by shared links- TrialSHARP
Shares Sorafenib, Hepatocellular carcinoma.
- CompanySirtex Medical
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialREFLECT
Shares Sorafenib, Hepatocellular carcinoma.
- CompanyBoston Scientific
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialIMbrave050
Shares Hepatocellular carcinoma and the tag failure.
- TrialLEAP-002
Shares Hepatocellular carcinoma and the tag failure.
- CompanyBayer
Shares Sorafenib, Hepatocellular carcinoma.
- TermDosimetry
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.